Lung cancer with EGFR PACC mutations: a practical review of available treatment options and novel therapies on the horizon
Julia M Berg, Hollis Viray, Jenna Green, Paul A VanderLaan, Susumu S Kobayashi, Xiuning Le, Daniel B Costa, Deepa Rangachari · 2026
Read Lung cancer with EGFR PACC mutations: a practical review of available treatment options and novel therapies on the horizon by Julia M Berg, Hollis Viray, Jenna Green, Paul A VanderLaan, Susumu S Kobayashi, Xiuning Le, Daniel B Costa, Deepa Rangachari (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13263868.txt.
Description
Julia M Berg and colleagues reviewed in 2026 treatment choices for a family of uncommon EGFR changes in lung cancer grouped by their shape, called PACC mutations. Together they account for more than a tenth of EGFR mutations, yet trials mostly enrolled the two classic types. Their practical review opens with a clinic case to ground the discussion.
Laboratory models show these mutations answer best to second-generation blockers such as afatinib. That drug alone carries approval covering two of the mutations, G719X and S768I. The authors weigh afatinib against the newer osimertinib and against combination regimens for first treatment. They balance tumor control against side effects and patient preference in the palliative setting. Data limits receive frank treatment throughout. Trials aimed squarely at this subgroup are running and may redraw the guidance soon.
Catalog record
| CREATOR | Julia M Berg, Hollis Viray, Jenna Green, Paul A VanderLaan, Susumu S Kobayashi, Xiuning Le, Daniel B Costa, Deepa Rangachari |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 30 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |